The Pfizer COVID Vaccine Prevented an Estimated 690,000 U.S. Hospitalizations and 110,000 Deaths
A new study from researchers associated with the Pfizer-BioNTech COVID vaccine describes the “profound health and economic impact” it had on the U.S. in 2021.
The study found the two-dose series of the vaccine, the most widely used against COVID in the U.S., prevented an estimated 8.7 million symptomatic COVID cases, 690,000 hospitalizations, and 110,000 deaths.
The peer-reviewed study was published in the Journal of Medical Economics.
The researchers used modeling, real-world, and trial data to estimate the impact of the vaccine.
The team estimates the vaccine was associated with productivity gains of $43.7 billion, stemming from the overall reduction of cases.
Most of the gain (64.3%) was related to preventing lost workdays during illness, while over a third (35.7%) stemmed from avoided productivity losses due to death.
The researchers also credit the vaccine with saving an estimated $30.4 billion in healthcare costs, largely driven by averted inpatient costs.
The Pfizer-BioNTech COVID vaccine was the first to be available in the U.S., eventually reaching nearly six in ten Americans who were fully vaccinated in 2021.
The vaccine is marketed under the brand name Comirnaty.
Why it matters:
“The analyses show that the Pfizer-BioNTech COVID-19 vaccine contributed substantial public health impact in the US in 2021, and had a deep effect on the trajectory of the pandemic,” said lead author Manuela Di Fusco in a statement released with the study.